Two injections, two entirely different jobs

Both arrive via a needle, so it is easy to assume they work in the same way. They do not — and the difference is not a matter of degree.

A ChondroFiller injection is an ultrasound-guided procedure that places an injectable collagen scaffold directly into a focal cartilage defect. Once inside the lesion, the gel polymerises and physically occupies the damaged area, providing the structural matrix the body needs to begin repair. The target is the defect itself.

Viscosupplementation — a hyaluronic acid (HA) injection — is delivered into the general joint cavity. It restores the thickness and lubricating quality of synovial fluid, reducing friction between articulating surfaces and easing pain. It does not alter or reconstitute the cartilage surface. Relief typically lasts three to six months, after which a repeat course is usually needed.

Think of it this way: one fills a pothole, the other oils the road surface — if a focal defect is the underlying problem, only one of those actions addresses it. Selecting HA when a discrete structural lesion is present does not treat the lesion; it leaves it to progress, potentially enlarging over time.

How the ChondroFiller injection works as a scaffold

The collagen gel that forms ChondroFiller injection is acellular — it contains no donor cells — and is composed of Type I collagen, the same structural protein found in healthy articular cartilage. Once placed into the defect, it responds to body temperature and polymerises within three to five minutes, forming a dimensionally stable three-dimensional hydrogel that conforms to the shape of the lesion without requiring fixation or fibrin glue.

That physical presence is only the first step. The scaffold's therapeutic role is chemotactic: the collagen matrix acts as a biochemical signal, drawing the patient's own progenitor cells inward from surrounding subchondral bone and synovial tissue. This process — known as matrix-induced chondrogenesis — recruits cells that would otherwise have no route into an avascular cartilage defect. Inside the scaffold, conditions favour differentiation toward chondrocyte-like cells capable of producing repair tissue.

Evidence for this cell in-growth is not theoretical. A 2025 ex vivo study measured a 2.4-fold increase in DNA content within the collagen scaffold — a direct indicator of progenitor cell migration into the matrix, and the clearest published support for the proposed mechanism.

ChondroFiller injection holds CE-marking as a Class III medical device, the highest-risk classification in European regulation, reflecting the performance and safety requirements applied before clinical use.

What viscosupplementation actually does

Synovial fluid in a healthy joint is thick and elastic — a medium that both cushions and lubricates the articulating surfaces with each movement. In osteoarthritis, the concentration of native hyaluronic acid within that fluid falls, reducing its viscosity and its ability to protect cartilage surfaces from mechanical stress. Viscosupplementation replenishes that deficit: HA injected into the joint cavity restores the fluid's rheological properties, reducing surface friction and easing the load experienced with everyday movement.

Cochrane-level evidence — including the Bellamy et al. (2006) systematic review — confirms that HA does not regenerate or structurally alter articular cartilage. The benefit is symptomatic and palliative, which is not a limitation where the indication fits. For patients with mild-to-moderate diffuse osteoarthritic wear across multiple joint surfaces, managing pain and preserving function through viscosupplementation is a legitimate, well-supported pathway. Relief typically persists for three to six months; repeat injection cycles are the expected pattern for ongoing maintenance, not a sign of treatment failure.

Where precision matters: applied over a focal structural defect rather than diffuse wear, HA may provide some pain relief, but the underlying lesion remains entirely untreated — a distinction with real clinical consequences, explored in the following section.

Matching the right injection to the lesion type

Scans distinguish the two conditions before any treatment decision is possible. A focal cartilage defect — ICRS Grade 3 (penetrating more than half the cartilage depth) or Grade 4 (full-thickness, with bare bone exposed) — is a discrete structural hole within an otherwise functional joint. Diffuse osteoarthritic wear is a different problem: degradation spread across multiple joint surfaces, without a single repairable lesion to target.

The avascular nature of articular cartilage makes this distinction clinically decisive. Because no blood supply reaches the joint surface, neither repair signals nor progenitor cells can enter a focal defect from the circulation — the biological route that heals most other tissues simply does not exist here. Focal defects therefore do not spontaneously resolve; without a scaffold to bridge the gap, the site tends to fill gradually with mechanically inferior fibrocartilage or remain as a bare-bone area.

Biomechanical modelling reinforces the case for structural intervention: small and average-sized focal defects increase maximum compressive strains in adjacent cartilage by approximately 50% and 100% respectively. Over time, that abnormal loading accelerates wear in the surrounding tissue — turning an isolated lesion into a wider mechanical problem.

For a discrete Grade 3–4 defect, ChondroFiller injection addresses the underlying biology by providing the scaffold the avascular environment cannot supply naturally. For diffuse mild-to-moderate osteoarthritic wear, viscosupplementation targets symptoms and joint-fluid quality rather than the cartilage surface itself. These are not equivalent choices for a focal lesion; one treats the structure, the other manages the joint around it.

Clinical evidence for ChondroFiller injection outcomes

The most cited knee data come from a prospective post-market clinical follow-up study by Jerosch et al., which recorded a mean IKDC score improvement of 32.4 points sustained at three-year follow-up. The MCID — the minimum clinically important difference, the threshold below which patients cannot reliably perceive a benefit — is 16.7 points for the IKDC scale. Clearing it by nearly double suggests the improvement registered in daily function, not only in scores.

MRI findings support the functional data. MOCART scores, which grade the structural quality of cartilage repair on imaging, rose from 65.3 at four weeks to 81.6–84.3 at one year — consistent with progressive scaffold maturation and greater than 80% defect filling with integration into surrounding native tissue. A PMC-indexed arthroscopic case series extended the evidence to the hip, applying ChondroFiller to full-thickness chondral defects in femoroacetabular impingement patients and positioning the approach favourably against microfracture, whose fibrocartilaginous repair tissue has been shown to deteriorate beyond the two-to-three-year mark.

ChondroFiller's published data comprise largely single-arm studies and manufacturer-sponsored series; no large randomised controlled trial has yet reported. This is a developing evidence base, and it sits at a different level of maturity from the Cochrane-reviewed trial programme underpinning HA viscosupplementation within its own indication. That asymmetry is worth acknowledging plainly — not as a reason to dismiss the scaffold approach, but as honest context for shared decision-making at consultation. The broader hydrogel scaffold science, meanwhile, consistently demonstrates endogenous progenitor cell recruitment and hyaline-quality tissue formation in relevant models, lending mechanistic credibility to what the clinical series report.

When both injections have a role — and when to seek assessment

Neither treatment automatically excludes the other. Some patients present with both a focal structural lesion and degraded joint fluid — a discrete Grade 3–4 defect within a joint whose synovial environment has also deteriorated. In that setting, ChondroFiller injection may address the structural hole while HA viscosupplementation manages joint-wide lubrication; each operates on a different part of the problem, and neither substitutes for the other.

The practical starting point, however, is accurate characterisation of what is actually present. MRI confirms whether pathology is focal or diffuse, establishes defect depth, and provides a working estimate of size. That distinction — not pain severity or symptom duration — determines which injection pathway is clinically relevant. Choosing HA for a focal Grade 3–4 defect leaves the underlying lesion structurally unaddressed; applying a scaffold injection to purely diffuse osteoarthritic wear misidentifies the problem from the outset. The question to put to a specialist is not 'which injection?' but 'what does my imaging actually show?' — the answer to that determines whether a structural or symptomatic approach, or a combination of both, is warranted.

For patients whose scan suggests a focal chondral defect, specialist cartilage assessment before committing to any injection pathway is the appropriate next step: to confirm grading, assess lesion size, and establish whether ChondroFiller injection or an alternative restorative approach fits the presentation. That assessment is available at the London Cartilage Clinic on Harley Street; consultations can be arranged via londoncartilage.com.

1. [1] The effect of articular cartilage focal defect size andlocation in whole knee biomechanics models. (2020). https://doi.org/10.1115/1.4044032 https://doi.org/10.1115/1.4044032